Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Gilead HCV drug sales down in 2017 third quarter compared with 2016

Gilead announced that combined third-quarter sales for Harvoni, Sovaldi, Epclusa and Vosevi were $2.2 billion compared with $3.3 billion the third quarter of 2016, related to fewer patients initiating treatment and increased drug competition.

Published
31 October 2017
From
Healio
More than 6 million treated for hepatitis globally

Since 2015, nearly 3 million people initiated treatment for hepatitis C, and in 2016 alone nearly 3 million initiated hepatitis B treatment, according to an announcement from the World Health Organization in conjunction with the World Hepatitis Summit.

Published
31 October 2017
From
Healio
Michigan Sees Hepatitis A Outbreak in Gay Men

State health officials investigating a hepatitis A outbreak in southeast Michigan are reporting an increase in cases among men who are sexually active with men.

Published
31 October 2017
From
U.S. News & World Report
Hepatitis C test-and-treat programme reduces HCV by two-thirds among men who have sex with men in Swiss HIV Cohort

A systematic policy of test-and-treat cured 99% of men who have sex with men with hepatitis C in the Swiss HIV Cohort in an 8-month period and

Published
30 October 2017
By
Keith Alcorn
Curing hepatitis C with DAAs linked to 71% reduction in liver cancer

People who achieved a sustained response to hepatitis C treatment lowered their risk of hepatocellular carcinoma by around 70%, regardless of whether they were treated with new direct-acting

Published
30 October 2017
By
Liz Highleyman
High rate of hepatitis C reinfection in German men who have sex with men

Around one in seven gay and bisexual men cured of hepatitis C at major treatment centres in Germany has become reinfected since 2014, according to findings from

Published
28 October 2017
By
Keith Alcorn
Hepatitis C halved in Spanish people living with HIV in one year due to treatment

Spain is making dramatic progress towards eliminating hepatitis C in people living with HIV because of widespread use of direct-acting antivirals, Juan Berenguer of Hospital Gregorio Marañón, Madrid,

Published
27 October 2017
By
Keith Alcorn
New EACS treatment guidelines

Everyone with HIV and hepatitis C virus (HCV) co-infection should receive direct-acting antiviral treatment for hepatitis C and should receive the same treatment for hepatitis C as

Published
26 October 2017
By
Keith Alcorn
Health Group Challenges Gilead Patents In The US On Grounds Of Lack Of Novelty

A health advocacy group today announced that it has challenged a set of United States patents for a hepatitis C medicine. The group says drug maker Gilead Sciences has obtained unmerited patents for sofosbuvir, blocking millions of US patients from affordable treatment.

Published
26 October 2017
From
Intellectual Property Watch
Daily aspirin therapy linked to lower liver cancer risk

People with hepatitis B virus (HBV) who took an aspirin a day – often recommended to help prevent cardiovascular disease – had a lower risk of developing

Published
26 October 2017
By
Liz Highleyman

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.